RecruitingNCT02572778

Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer

Establishment of Primary Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer for Preclinical Evaluation of Targeted Therapies.

Sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Enrollment

40 participants

Start Date

Sep 1, 2015

Study Type

OBSERVATIONAL

Conditions

Squamous Cell Carcinoma of the Head and Neck

Summary

The investigators want to have a collection of fresh primary or recurrent tumor tissue for establishment of patients-derived xenografts in order to: generate a biobank of in vivo patient xenografts representing the different subgroups of tumors for head and neck cancer * perform genetic and transcriptional profiling of the primary, metastatic tumors and xenograft tumors * evaluate the efficacy of new targeted agents, whether or not in combination with standard treatment options * evaluate biomarkers of drug sensitivity * study primary and secondary (acquired) resistance in these models

Eligibility

Min Age: 18 Years

Inclusion Criteria5

In the first phase, all patients with primary or recurrent/ metastatic disease of head and neck cancer can be included pre-operatively or before a tumor biopsy after obtaining informed consent
Data on stage, grade, histology, adjuvant treatment, responses, relapse should be available
Follow-up data should be available
Patients with recurrent disease are allowed
Written informed consent

Interventions

PROCEDURELocal biopsy in the tumor

A tumor biopsy of 0.5 cm2 or more will be collected from every patient during surgery or endoscopy after informed consent and if there is enough material after review by the pathologist.